Slayback’s Belrapzo Non-Infringement Judgement Is Upheld On Appeal
In Dispute Over Dedication-Disclosure Doctrine
Executive Summary
Slayback Pharma has succeeded in defending itself on appeal that it did not infringe certain patents shielding Eagle Pharmaceuticals’ Belrapzo rapid-infusion bendamustine product, after a district court applied the dedication-disclosure doctrine to bar the originator’s claim.